Patients with immune-mediated inflammatory diseases (IMIDs) are at increased risk of herpes zoster (HZ), particularly those ...
Objectives The additional impact of coexisting Sjögren’s syndrome (SS) on cardiac involvement in patients with systemic lupus ...
Moreover, as some clinical trials have excluded them, the efficacy of some immunosuppressants for this subset of patients has not been strictly confirmed. In this study, we aimed to investigate the ...
Background SLE features aberrant type I interferon production, with the stimulator of interferon genes (STING) pathway acting as a key upstream driver. However, its expression patterns in patients ...
Objective Fatigue is a common, multifaceted symptom in SLE which is difficult to treat. There has been a lack of broadly accepted SLE-specific assessment tools for fatigue. This study assessed the ...
Systemic lupus erythematosus (SLE) is a profoundly heterogeneous disease in which clinical phenotype emerges from the interplay of autoantibody profiles, organ involvement, cytokine signatures, ...
Objective This study aimed to compare 25-hydroxyvitamin D (25-(OH)D) levels and peripheral lymphocyte subsets between children with new childhood-onset SLE and healthy controls across different ...
Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by exocrinopathy, extraglandular inflammation, and marked B-cell activation. Dryness, fatigue, pain, systemic organ ...
Objective Lupus nephritis (LN) is a potentially severe manifestation of SLE, often resulting in permanent kidney damage. We investigated whether polygenic and/or epigenetic risk is associated with ...
The case for early biologic therapy in systemic lupus erythematosus (SLE) is intuitively appealing but requires closer scrutiny. First, ‘early’ is poorly defined with UK survey data showing a mean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results